Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Novartis Broadens VISION On Radioligands

Firm Prepares For Expansion Into Prostate Cancer

Executive Summary

Phase III trial presented at ASCO shows 177lutetium-PSMA-617 improved radiographic PFS and OS in advanced prostate cancer patients. Novartis execs say the firm is ready for the marketing challenge. 

You may also be interested in...



Novartis Lays A New Foundation In Prostate Cancer With Second Radioligand Launch

"We have big plans," oncology president Susanne Schaffert said in an interview about launching Pluvicto, its new radioligand therapy for prostate cancer.

Belgium's Precirix Beats Biotech Blues With Major Cash Boost

Despite the sector's woes, strong companies that generate strong patient data based on solid science have a promising future, Precirix CEO Ruth Devenyns tells Scrip.

Novartis’s John Tsai On The Four Philosophies Driving R&D

Scrip spoke with global development head and chief medical officer John Tsai about the factors Novartis considers when it decides which R&D programs to advance, including externally sourced assets. 

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

SC144486

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel